PitchSend

Investor Presentaiton

Investor presentation First three months of 2017 Slide 26 Novo Nordisk has a strong leadership position within the growing diabetes care market Global diabetes care market by treatment class OAD Global diabetes care value market share GLP-1 Insulin Novo Nordisk AstraZeneca Sanofi Novartis Eli Lilly Merck Takeda GSK 30% DKK billion 500 450 400 350 300 250 200 150 100 50- 0 Feb 2007 Total market: CAGR¹ 15.2% Injectables: CAGR¹ 19.4% CAGR¹ 34.3% 20% 10% CAGR¹ 17.9% CAGR¹ 10.6% 0% Feb 2017 Feb 2007 1 CAGR for 10-year period. OAD: Oral Anti-diabetic Source: IMS Monthly MAT February, 2017 value figures changing diabetes® Source: IMS Monthly MAT February, 2017 value figures 27% Feb 2017 novo nordisk

View entire presentation